Verwijs Marinus 4
4 · Aerovate Therapeutics, Inc. · Filed Jun 14, 2024
Insider Transaction Report
Form 4
Verwijs Marinus
Senior Vice President, CMC
Transactions
- Exercise/Conversion
Common Stock
2024-06-14$14.59/sh+10,600$154,654→ 10,600 total - Sale
Common Stock
2024-06-14$25.00/sh−10,600$265,000→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-06-14−10,600→ 68,800 totalExercise: $14.59Exp: 2032-03-20→ Common Stock (10,600 underlying)
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023.
- [F2]25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.